E

Evolus

Direct-to-professional aesthetic neurotoxin provider

Overview

Evolus develops cash-pay medical aesthetics products sold directly to dermatologists and plastic surgeons. Its flagship Jeuveau (prabotulinumtoxinA-xvfs) is a prescription neurotoxin that temporarily relaxes small facial muscles to reduce dynamic wrinkles for about three to six months; Evolus is adding Evolysse, a line of hyaluronic acid dermal fillers approved in 2025. The company differentiates itself with a focused neurotoxin and skincare product lineup, a growing direct-sales network of over 16,000 accounts, and consumer-facing digital marketing in clinics. Its goal is to grow revenue by expanding its product portfolio and market reach in the U.S. and internationally while continuing commercialization efforts after its IPO.

Work here?Claim your company

About Evolus

Simplify's Rating
Not yet rated

We're working on gathering enough insights on this company, check back soon!

Industries

Enterprise SoftwareHealthcare

Company Size

201-500

Company Stage

IPO

Headquarters

Newport Beach, CA

Founded

2012

Get referred to Evolus

See people who can refer or advise you

Funding

Total Funding

$488.6M

Above

Industry Average

Funded Over

5 Rounds

Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Debt Funding Comparison Coming Soon

Benefits

  • Remote Work Options
  • Hybrid Work Options
  • Stock Options
  • Company Equity
  • Mental Health Support

Growth & Insights

6 month growth

0%

1 year growth

0%

2 year growth

0%

Recently Posted Jobs

Sign up to get curated job recommendations

Evolus is Hiring for 21 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs